12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ruxolitinib regulatory update

FDA accepted and granted Priority Review to an NDA from Incyte for ruxolitinib to treat myelofibrosis. The PDUFA date is Dec. 3. An...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >